Advances in the treatment of heart failure with a preserved ejection fraction

Current Opinion in Cardiology

Volumn 23, Issue 3, 2008, Pages 233-240

  Das, Aparajita ^a   Abraham, Selwin ^a   Deswal, Anita ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Diastolic heart failure; Heart failure; Treatment

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIGITALIS; DIGOXIN; IRBESARTAN; MCC 135; NEBIVOLOL; PERINDOPRIL; PLACEBO; SPIRONOLACTONE; UNCLASSIFIED DRUG;

BLOOD PRESSURE; CLINICAL TRIAL; COMORBIDITY; DIASTOLIC BLOOD PRESSURE; EXERCISE; HEART EJECTION FRACTION; HEART FAILURE; HEART RATE; HUMAN; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; STROKE VOLUME; TREATMENT OUTCOME;

EID: 41749096604     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3282f73317     Document Type: Review

References (40)

1. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004; 43:317-327.
2. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33:1948-1955.
3. Kitzman DW, Gardin JM, Gottdiener JS, et al. Importance of heart failure with preserved systolic function in patients ≥65 years of age. Am J Cardiol 2001; 87:413-419.
4. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24:442-463.
5. Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003; 4 (Suppl 7):S21-S30.
6. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355:251-259. A recent study from Olmstead County examining secular trends in the prevalence and outcomes of HF-PEF.
7. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355:260-269. A recent study from a large Canadian cohort of patients hospitalized with HF, examining the characteristics and outcomes of patients with HF-PEF compared with those of patients with depressed ejection fraction.
8. Adams KF, Lindenfeld J, Arnold JMO, et al. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006; 12:10-38. The latest national practice guidelines for HF-PEF.
9. Redfield MM. Heart failure with normal ejection fraction. In: Libby P, Bonow RO, Mann DL, Zipes DP, editors. Braunwald's heart disease: a textbook of cardiovascular medicine. 8th ed. Philadelphia, PA: Saunders Elsevier; 2007. pp. 641-657. A very comprehensive review of the current understanding of the pathophysiology of HF-PEF.
10. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 2002; 105:1503-1508.
11. Kass DA, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 2004; 94:1533-1542.
12. Little WC, Brucks S. Therapy for diastolic heart failure. Prog Cardiovasc Dis 2005; 47:380-388.
13. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure - abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350:1953-1959.
14. Zile MR, Gaasch WH, Carroll JD, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 2001; 104:779-782.
15. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003; 107:714-720.
16. Borlaug BA, Melenovsky V, Russell SD, et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006; 114:2138-2147. This study demonstrates the possible importance of an impaired chronotropic and vasodilator response in patients with HF-PEF as a pathophysiological mechanism and possibly leading to a target for therapy of HF-PEF.
17. Maurer MS, King DL, El Khoury RL, et al. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. J Card Fail 2005; 11:177-187.
18. Yamamoto K, Masuyama T, Sakata Y, et al. Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc Res 2000; 47:274-283.
19. Martos R, Baugh J, Ledwidge M, et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007; 115:888-895.
20. Slatton ML, Irani WN, Hall SA, et al. Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm? J Am Coll Cardiol 1997; 29:1206-1213.
21. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
22. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368:581-588.
23. Setaro JF, Zaret BL, Schulman DS, et al. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990; 66:981-986.
24. Hung MJ, Cherng WJ, Kuo LT, Wang CH. Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Int J Clin Pract 2002; 56:57-62.
25. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin- converting enzyme inhibitors. Am J Cardiol 1997; 80:207-209.
26. Aronow WS, Kronzon I. Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993; 71:602-604.
27. Ferguson DW, Berg WJ, Sanders JS, et al. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation 1989; 80:65-77.
28. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362:777-781.
29. Cleland JGF, Tendera M, Adamus J, et al. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 2006; 27:2338-2345. One of the two large completed randomized clinical trials evaluating treatment with RAS blockade in patients with HF-PEF.
30. Kuroedov A, Cosentino F, Luscher TF. Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. Cardiovasc Drug Rev 2004; 22:155-168.
31. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26:215-225.
32. Massie BM, Abdalla I. Heart failure in patients with preserved left ventricular systolic function: do digitalis glycosides have a role? Prog Cardiovasc Dis 1998; 40:357-369.
33. Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002; 288:2144-2150.
34. Ahmed A, Rich MW, Fleg JL, et al. Effects of Digoxin on morbidity and mortality in diastolic heart failure: The Ancillary Digitalis Investigation Group Trial. Circulation 2006; 114:397-403. A subgroup analysis examining the effects of digitalis in the subgroup of patients with HF-PEF enrolled in the ancillary arm of the larger Digitalis Investigators Group Trial of patients with HF.
35. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105:1387-1393.
36. Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104:1464-1470.
37. Little WC, Zile MR, Kitzman DW, et al. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005; 11:191-195.
38. Zile MR. Treating diastolic heart failure with statins: "phat" chance for pleiotropic benefits. Circulation 2005; 112:300-303.
39. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005; 112:357-363.
40. Carson P, Massie BM, McKelvie R, et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 2005; 11:576-585.